Literature DB >> 31606521

Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system).

Georgios Stamatis1, Gunda Leschber2, Birte Schwarz3, Diana Lütke Brintrup4, Claudia Ose4, Gerhard Weinreich5, Bernward Passlick6, Erich Hecker7, Christian Kugler8, Hendrik Dienemann9, Thomas Krbek10, Stephan Eggeling11, Rudolf Hatz12, Michael Rolf Müller13, Walter Weder14, Clemens Aigner3, Karl-Heinz Jöckel4.   

Abstract

OBJECTIVES: For early stage non-small cell lung cancer (NSCLC) retrospective data of functionally compromised patients undergoing segmentectomy showed equal outcomes for perioperative complications and quality of life (QoL) compared with lobectomy patients. However no prospectively randomized data comparing patients eligible for both procedures are available.
MATERIALS AND METHODS: We conducted a prospective, randomized, multicenter phase III trial and investigated perioperative complications and QoL in patients with NSCLC stage IA (7th edition) undergoing segmentectomy versus lobectomy. The EORTC Questionnaire Core-30 (QLQ C-30) supplemented by thirteen-item lung cancer-specific module (LC13) was assessed before surgery, at discharge, 6 weeks, 3, 6 and 12 months post-surgery.
RESULTS: 108 patients with verified or suspected NSCLC up to 2 cm diameter were enrolled, whereby 54 were assigned to lobectomy and 54 to segmentectomy. Due to nodal disease, tumor size and surgical reasons estimated during the operation, eight patients of the segmentectomy group received a lobectomy. In hospital and 90 days mortality was 0% in both groups. Perioperative complications were observed in 6 (11.3%) patients after segmentectomy and in 8 patients (14.8%) after lobectomy (p = 0.563), while the 90-day morbidity were 17% and 25.9% (9 and 14 patients), respectively (p = 0.452). Twelve months after surgery, there was a significant deterioration to the baselines of physical (p < 0.001) and cognitive functioning (p = 0.025), dyspnea (p < 0.001) and fatigue (p = 0.003) in the lobectomy group. Dyspnea showed a faster recovery in the segmentectomy compared to lobectomy group with statistical significance (p = 0.016 after 12 months).
CONCLUSION: In patients with early-stage NSCLC, segmentectomy is associated with a statistically not significant lower perioperative morbidity and appears to provide a superior recovery in QoL compared with lobectomy patients.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Morbidity; Mortality; NSCLC stage IA; Quality of life; Segmentectomy versus lobectomy

Mesh:

Year:  2019        PMID: 31606521     DOI: 10.1016/j.lungcan.2019.09.021

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  14 in total

1.  Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer.

Authors:  Dong Woog Yoon; Chu Hyun Kim; Soohyun Hwang; Yoon-La Choi; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Sumin Shin; Ho Yun Lee
Journal:  Insights Imaging       Date:  2022-06-17

Review 2.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

3.  Postoperative Short-term Outcomes Between Sublobar Resection and Lobectomy in Patients with Lung Adenocarcinoma.

Authors:  Jiaqi Zhang; Wenliang Bai; Chao Guo; Lei Liu; Guige Wang; Cheng Huang; Yeye Chen; Ye Zhang; Shanqing Li
Journal:  Cancer Manag Res       Date:  2020-10-01       Impact factor: 3.989

4.  Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review.

Authors:  Alberto Codima; Willian das Neves Silva; Ana Paula de Souza Borges; Gilberto de Castro
Journal:  Support Care Cancer       Date:  2020-05-09       Impact factor: 3.603

5.  Anatomical segmentectomy versus pulmonary lobectomy for stage I non-small-cell lung cancer: patients selection and outcomes from the European Society of Thoracic Surgeons database analysis.

Authors:  Davide Tosi; Mario Nosotti; Gianluca Bonitta; Paolo Mendogni; Luca Bertolaccini; Lorenzo Spaggiari; Alex Brunelli; Enrico Ruffini; Pierre Emmanuel Falcoz
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-04-19

6.  Quality of life in the era of limited resections.

Authors:  Ulaş Kumbasar
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-04-26       Impact factor: 0.332

7.  Short-term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm.

Authors:  Marc Darras; Amaya Ojanguren; Céline Forster; Matthieu Zellweger; Jean Yannis Perentes; Thorsten Krueger; Michel Gonzalez
Journal:  Thorac Cancer       Date:  2020-12-03       Impact factor: 3.500

8.  The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases.

Authors:  Michelle C Salazar; Maureen E Canavan; Samantha L Walters; Sitaram Chilakamarry; Theresa Ermer; Justin D Blasberg; James B Yu; Cary P Gross; Daniel J Boffa
Journal:  JTO Clin Res Rep       Date:  2021-01-21

9.  Intersegmental plane simulation based on the bronchus-vein-artery triad in pulmonary segmentectomy.

Authors:  Guobing Xu; Jianting Du; Chun Chen; Wei Zheng; Hao Chen; Jiazhou Xiao; Weixin Wu
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

Review 10.  Segmentectomy and Wedge Resection for Elderly Patients with Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Peiyu Wang; Shaodong Wang; Zheng Liu; Xizhao Sui; Xun Wang; Xiao Li; Mantang Qiu; Fan Yang
Journal:  J Clin Med       Date:  2022-01-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.